Enoxaparin as Treatment for Vulvodynia

Phase 2

Completed

• Conditions: Vulvodynia
• Interventions: Drug: Clexane (enoxaparin)

• Registration Number: NCT00874484
• Lead Sponsor: Western Galilee Hospital-Nahariya

Brief Summary

The investigators hypothesize that injections of Low molecular weight heparin (LMWH) \[enoxaparin\] will reduce pain in women with vulvodynia.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-03
• Study First Submitted: 2009-03-31
• Study First Submitted QC: 2009-04-01
• Study First Posted: 2009-04-02
• Primary Completion: 2011-04
• Study Completion: 2011-05
• Status Verified: 2020-05
• Last Update Submitted: 2020-05-19
• Last Update Posted: 2020-05-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 40

Inclusion Criteria

• women with vulvodynia

Exclusion Criteria

• women without vulvodynia

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
2	Clexane (enoxaparin)	-
1	Clexane (enoxaparin)	-

Primary Outcome Measures

Name	Time	Method
vestibular pain	one year

Trial Locations

Locations (1)

Western Galilee Hospital- Nahariya; 🇮🇱 Nahariya, Israel